Terry W Moody1, Robert T Jensen2. 1. Department of Health and Human services, National Cancer Institute, Center for Cancer Training. Bethesda, Maryland, USA. 2. National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, Digestive Diseases Branch, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: To discuss recent advances of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide (VIP/PACAP) receptors in the selected central nervous system (CNS) and inflammatory disorders. RECENT FINDINGS: Recent studies provide evidence that PACAP plays an important role in a number of CNS disorders, particularly the pathogenesis of headaches (migraine, etc.) as well as posttraumatic stress disorder and drug/alcohol/smoking addiction. VIP has important therapeutic effects in a number of autoimmune/inflammatory disorder such as rheumatoid arthritis. In some cases, these insights have advanced to therapeutic trials. SUMMARY: Recent insights from studies of VIP/PACAP and their receptors in both CNS disorders (migraine, posttraumatic stress disorder, addiction [drugs, alcohol, smoking]) and inflammatory disorders [such as rheumatoid arthritis] are suggesting new treatment approaches. The elucidation of the importance of VIP/PACAP system in these disorders combined recent development of specific drugs acting on this system (i.e., monoclonal VIP/PACAP antibodies) will likely lead to importance novel treatment approaches in these diseases.
PURPOSE OF REVIEW: To discuss recent advances of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide (VIP/PACAP) receptors in the selected central nervous system (CNS) and inflammatory disorders. RECENT FINDINGS: Recent studies provide evidence that PACAP plays an important role in a number of CNS disorders, particularly the pathogenesis of headaches (migraine, etc.) as well as posttraumatic stress disorder and drug/alcohol/smoking addiction. VIP has important therapeutic effects in a number of autoimmune/inflammatory disorder such as rheumatoid arthritis. In some cases, these insights have advanced to therapeutic trials. SUMMARY: Recent insights from studies of VIP/PACAP and their receptors in both CNS disorders (migraine, posttraumatic stress disorder, addiction [drugs, alcohol, smoking]) and inflammatory disorders [such as rheumatoid arthritis] are suggesting new treatment approaches. The elucidation of the importance of VIP/PACAP system in these disorders combined recent development of specific drugs acting on this system (i.e., monoclonal VIP/PACAP antibodies) will likely lead to importance novel treatment approaches in these diseases.
Authors: Irene Ramos-Álvarez; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Paola Moreno; Terry W Moody; Jerome L Maderdrut; David H Coy; Robert T Jensen Journal: Peptides Date: 2015-02-16 Impact factor: 3.750
Authors: Kerry J Ressler; Kristina B Mercer; Bekh Bradley; Tanja Jovanovic; Amy Mahan; Kimberly Kerley; Seth D Norrholm; Varun Kilaru; Alicia K Smith; Amanda J Myers; Manuel Ramirez; Anzhelika Engel; Sayamwong E Hammack; Donna Toufexis; Karen M Braas; Elisabeth B Binder; Victor May Journal: Nature Date: 2011-02-24 Impact factor: 49.962
Authors: Michael L Lehmann; Tomris Mustafa; Adrian M Eiden; Miles Herkenham; Lee E Eiden Journal: Psychoneuroendocrinology Date: 2012-10-11 Impact factor: 4.905
Authors: K B Mercer; B Dias; D Shafer; S A Maddox; J G Mulle; P Hu; J Walton; K J Ressler Journal: Transl Psychiatry Date: 2016-12-13 Impact factor: 6.222